Small molecule cancer drugs is in the very early stages of development for use in the treatment of cancer. In recent years, it has been found that cancer cells secrete chemicals as a defense against cancer treatments. These chemicals can be detected by the body's immune system, and these chemicals are often found within tumors. The body's immune system recognizes some cancer cells as foreign particles that may be harmful to the body. With growing cancer burden worldwide, key pharmaceutical and biotechnology companies are focused on developing novel therapies and medications for the treatment of different types of cancer. With growing focus on small molecule cancer drugs, research and development activities are likely to surge in the near future. Hence, such factors can augment growth small molecule cancer drugs market in the near future. Recently, in November 2020, Genesis Therapeutics collaborated with Genentech for AI-driven multi-target drug discovery.
One of the most obvious factors aiding growth of the said market is the rapidly increasing incidence of cancer across the globe. As per the World Health Organization (WHO), in 2018, around 9.6 million deaths were reported due to cancer globally, of which 2.09 million cases were due to lung cancer. As per the same source, in 2018, around 9.6 million deaths were reported due to cancer globally, of which 2.09 million cases were due to lung cancer. Small molecule cancer drugs have been found successful in treating cancer as they can affect molecules such as a protein that may cause cancer. Hence, such factors can stimulate growth of the small molecule cancer drugs market.
Regardless of the advantageous factors, challenges such as high drug development costs can impede growth of the small molecule cancer drugs market. Drug development requires a significant amount of investment and thus limited number of companies are focused on small molecule cancer drugs R&D. Besides, the stringent regulatory frameworks can further inhibit growth of the market in the near future.
Small molecule inhibitory antibodies (S MIAs) are a new class of anti-cancer drugs that have high promise as effective anticancer agents. An SMIA is a protein complex that recognizes specific cancer cells. Once the SMIA recognizes the cancer cell, it triggers a biological response that destroys cancer. When it comes to geographical impact, North America seems to be gaining significant traction in the small molecule cancer drugs market. This is due to large incidences of cancer across the U.S. On the contrary, Asia Pacific is showing promising signs due to improving healthcare infrastructure in India and China.
No comments:
Post a Comment